SEC Filings
Cullinan's Cash Falls To $313.8 Million — It Expects Funding To Last Into 2029
Taiho's lung-cancer combination application is now expected to be completed in November, rather than by year-end.
Cullinan Therapeutics (CGEM) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Taiho's lung-cancer combination application is now expected to be completed in November, rather than by year-end.
SEC Filings
The passive position was dated September 30; Cullinan reported preliminary velinotamig results Sunday.
SEC Filings
The China study treated 12 patients, with interim results supporting Cullinan’s development plans beyond lupus.
SEC Filings
Patients given two step-up doses of CLN-049 had a 26% rate of cytokine release syndrome, versus 36% on one step-up dose.